Top
image credit: Adobe Stock

Oculis SA and EBAC join to drive ophthalmology innovation

October 18, 2022

The announced definitive business combination agreement is set to complete in H1 in 2023 in Lausanne, Switzerland and Amsterdam, Netherlands. It will create a Nasdaq-listed biopharmaceutical company under the name “Oculis Holding SA”, placing Oculis in position to become a leading global ophthalmic biopharma, with product candidates to address areas of significant medical needs affecting a growing number of patient populations. This includes products for diabetic macular oedema (DME), dry eye disease (DED), and neuro-retina indications, such as glaucoma.

Read More on Pharmaphorum